pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2022-32-2-253-259pulmo-3863Research ArticleКЛИНИЧЕСКАЯ ФАРМАКОЛОГИЯCLINICAL PHARMACOLOGYВозможности терапии эрдостеином в снижении частоты обострений хронической обструктивной болезни легкихThe potential of erdosteine to reduce the rate of exacerbations of chronic obstructive pulmonary diseasehttps://orcid.org/0000-0002-5999-2150АвдеевС. Н.AvdeevS. N.

Авдеев Сергей Николаевич – доктор медицинских наук, член-корр. Российской академии наук, профессор, заведующий кафедрой пульмонологии Института клинической медицины имени Н.В.Склифосовского Первого Московского государственного медицинского университета имени И.М.Сеченова; руководитель клинического отдела Научно-исследовательского института пульмонологии

SPIN-code: 1645-5524

119991, Россия, Москва, ул. Трубецкая, 8, стр. 2;115682, Россия, Москва, Ореховый бульвар, 28

 

Sergey N. Avdeev, Doctor of Medicine, Professor, Corresponding Member of Russian Academy of Sciences, Head of the Department of Pulmonology, N.V.Sklifosovsky Institute of Clinical Medicine,  I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Head of the Clinical Department, Federal Pulmonology Research Institute

SPIN-code: 1645-5524

ul. Trubetskaya 8, build. 2, Moscow, 119991, Russia; Orehovyy bul. 28, Moscow, 115682, Russia

avdeev@list.ruhttps://orcid.org/0000-0002-0685-4133ТрушенкоН. В.TrushenkoN. V.

Трушенко Наталья Владимировна – кандидат медицинских наук, ассистент кафедры пульмонологии Института клинической медицины имени Н.В.Склифосовского Первого Московского государственного медицинского университета имени И.М.Сеченова;  научный сотрудник научно-методического центра мониторинга и контроля болезней органов дыхания Научно-исследовательского института пульмонологии

119991, Россия, Москва, ул. Трубецкая, 8, стр. 2;115682, Россия, Москва, Ореховый бульвар, 28

Natal’ya V. Trushenko, Candidate of Medicine, Assistant, Department of Pulmonology, N.V.Sklifosovsky Institute of Clinical Medicine,  I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Researcher, Scientific and Methodological Center for Monitoring and Control of Respiratory Diseases, Federal Pulmonology Research Institute

ul. Trubetskaya 8, build. 2, Moscow, 119991, Russia; Orehovyy bul. 28, Moscow, 115682, Russia

trushenko.natalia@yandex.ruhttps://orcid.org/0000-0002-5536-9388ЧикинаС. Ю.ChikinaS. Yu.

Чикина Светлана Юрьевна – кандидат медицинских наук, ассистент кафедры пульмонологии Института клинической медицины имени Н.В.Склифосовского Первого Московского государственного медицинского университета имени И.М.Сеченова

119991, Россия, Москва, ул. Трубецкая, 8, стр. 2

Svetlana Yu. Chikina, Candidate of Medicine, Assistant Lecturer, Department of Pulmonology, N.V.Sklifosovsky Institute of Clinical Medicine,  I.M.Sechenov First Moscow State Medical University 

ul. Trubetskaya 8, build. 2, Moscow, 119991, Russia

svch@list.ruСувороваО. А.SuvorovaO. A.

Суворова Ольга Александровна – ординатор 1-го года кафедры пульмонологии Первого Московского государственного медицинского университета имени И.М.Сеченова

119991, Россия, Москва, ул. Трубецкая, 8, стр. 2

Olga A. Suvorova, 1st year Resident of Department of Pulmonology, N.V.Sklifosovsky Institute of Clinical Medicine,  I.M.Sechenov First Moscow State Medical University 

ul. Trubetskaya 8, build. 2, Moscow, 119991, Russia

olga.a.suvorova@mail.ruФедеральное государственное автономное образовательное учреждение высшего образования «Первый Московский государственный медицинский университет имени И.М.Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет); Федеральное государственное бюджетное учреждение «Научно-исследовательский институт пульмонологии» Федерального медико-биологического агентстваРоссияFederal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University); Federal Pulmonology Research Institute, Federal Medical and Biological Agency of RussiaRussian FederationФедеральное государственное автономное образовательное учреждение высшего образования «Первый Московский государственный медицинский университет имени И.М.Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет)РоссияFederal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)Russian Federation202202052022322253259Copyright © Авдеев С.Н., Трушенко Н.В., Чикина С.Ю., Суворова О.А., 20222022Авдеев С.Н., Трушенко Н.В., Чикина С.Ю., Суворова О.А.Avdeev S.N., Trushenko N.V., Chikina S.Y., Suvorova O.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/3863

При обострении хронической обструктивной болезни легких (ХОБЛ) ухудшается статус здоровья, повышаются частота госпитализаций, вероятность прогрессирования заболевания и риск неблагоприятного исхода. Одной из основных целей терапии стабильной ХОБЛ на сегодняшний день является снижение частоты обострений заболевания, в связи с этим крайне актуальным для клинической практики является расширение терапевтических возможностей в отношении данного показателя. Патогенетически обоснованным методом лечения ХОБЛ, направленным в т. ч. на снижение частоты обострений, является применение муколитических препаратов с антиоксидантными и противовоспалительными свойствами.

Целью работы явилось описание дополнительных возможностей фармакотерапии с использованием мукоативного препарата эрдостеина в качестве поддерживающей терапии ХОБЛ, направленной на профилактику обострений основного заболевания.

Заключение. Продемонстрировано, что применение эрдостеина у пациентов со стабильной ХОБЛ, в первую очередь II стадии по критериям Глобальной инициативы диагностики лечения и профилактики ХОБЛ (Global Initiative for Chronic Obstructive Lung Disease – GOLD), способствует снижению частоты и продолжительности обострений заболевания.

Exacerbations of COPD worsen health status, increase the frequency of hospitalizations, the likelihood of disease progression, and the risk of adverse outcomes. One of the main goals of the treatment of stable COPD today is to reduce the frequency of exacerbations of the disease. Thus, the expansion of suitable therapeutic options is extremely relevant for clinical practice. Use of mucolytic drugs with antioxidant and anti-inflammatory effects in COPD is justified by the pathogenetic mechanisms. These drugs are able to reduce the frequency of exacerbations, among other positive effects.

Aim

Aim. This article describes additional possibilities of pharmacotherapy using the mucoactive drug erdosteine as maintenance therapy for COPD aimed at preventing exacerbations of this disease.

Conclusion

Conclusion. The use of erdosteine in patients with stable COPD helps reduce the frequency and duration of exacerbations of the disease, primarily in the patients with stage II according to GOLD.

хроническая обструктивная болезнь легкихобострениемуколитические препаратыэрдостеин.COPDexacerbationmucolyticserdosteinСтатья опубликована при финансовой поддержке ООО «Си Эс Си ЛТД». ООО «Си Эс Си ЛТД» не несет ответственности за содержание статьи. Мнение ООО «Си Эс Си ЛТД» может отличаться от мнения авторов статьи и редакции. Подготовка статьи проводилась при финансовой поддержке ООО «Си Эс Си ЛТД», организации, представляющей на российском рынке оригинальный эрдостеин.The article was published with the financial support of LLC “CSC Ltd Russia”. LLC “CSC Ltd Russia” is not responsible for the content of the article. The opinion of LLC “CSC Ltd Russia” may differ from the opinion of the authors and editors of the article. The article was prepared with the financial support of LLC “CSC Ltd Russia”, an organization representing the original erdostein on the Russian market.ReferencesGlobal Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2022 Report. Available at: https://goldcopd.org/2022-gold-reports-2/Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2022 Report. Available at: https://goldcopd.org/2022-gold-reports-2/Aisanov Z., Avdeev S., Arkhipov V. et al. Russian guidelines for the management of COPD: algorithm of pharmacologic treatment. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 183–187. DOI: 10.2147/copd.s153770.Aisanov Z., Avdeev S., Arkhipov V. et al. Russian guidelines for the management of COPD: algorithm of pharmacologic treatment. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 183–187. DOI: 10.2147/copd.s153770.Wilkinson T.M.A., Donaldson G.C., Hurst J.R. et al. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2004; 169 (12): 1298–1303. DOI: 10.1164/rccm.200310-1443OC.Wilkinson T.M.A., Donaldson G.C., Hurst J.R. et al. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2004; 169 (12): 1298–1303. DOI: 10.1164/rccm.200310-1443OC.Vijayasaratha K., Stockley R.A. Reported and unreported exacerbations of COPD: analysis by diary cards. Chest. 2008; 133 (1): 34–41. DOI: 10.1378/chest.07-1692.Vijayasaratha K., Stockley R.A. Reported and unreported exacerbations of COPD: analysis by diary cards. Chest. 2008; 133 (1): 34–41. DOI: 10.1378/chest.07-1692.Aaron S.D., Donaldson G.C., Whitmore G.A. et al. Time course and pattern of COPD exacerbation onset. Thorax. 2012; 67 (3): 238–243. DOI: 10.1136/thoraxjnl-2011-200768.Aaron S.D., Donaldson G.C., Whitmore G.A. et al. Time course and pattern of COPD exacerbation onset. Thorax. 2012; 67 (3): 238–243. DOI: 10.1136/thoraxjnl-2011-200768.Perera W.R., Hurst J.R., Wilkinson T.M.A. et al. Infl tory changes, recovery and recurrence at COPD exacerbation. Eur. Respir. J. 2007; 29 (3): 527–534. DOI: 10.1183/09031936.00092506.Perera W.R., Hurst J.R., Wilkinson T.M.A. et al. Infl tory changes, recovery and recurrence at COPD exacerbation. Eur. Respir. J. 2007; 29 (3): 527–534. DOI: 10.1183/09031936.00092506.Donaldson G.C., Law M., Kowlessar B. et al. Impact of prolonged exacerbation recovery in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2015; 192 (8): 943–950. DOI: 10.1164/rccm.201412-2269OC.Donaldson G.C., Law M., Kowlessar B. et al. Impact of prolonged exacerbation recovery in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2015; 192 (8): 943–950. DOI: 10.1164/rccm.201412-2269OC.Авдеев С.Н., Трушенко Н.В., Гайнитдинова В.В. и др. Лечение обострений хронической обструктивной болезни легких. Терапевтический архив. 2018; 90 (12): 68–75. DOI: 10.26442/00403660.2018.12.000011.Avdeev S.N., Trushenko N.V., Gaynitdinova V.V. et al. [Treatment of exacerbations of chronic obstructive pulmonary disease]. Terapevticheskiy arkhiv. 2018; 90 (12): 68–75. DOI: 10.26442/00403660.2018.12.000011 (in Russian).Seemungal T.A., Donaldson G.C., Bhowmik A. et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 161 (5): 1608–1613. DOI: 10.1164/ajrccm.161.5.9908022.Seemungal T.A., Donaldson G.C., Bhowmik A. et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 161 (5): 1608–1613. DOI: 10.1164/ajrccm.161.5.9908022.Zheng J.P., Wen F.Q., Bai C.X. et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir. Med. 2014; 2 (3): 187–194. DOI: 10.1016/S2213-2600(13)70286-8.Zheng J.P., Wen F.Q., Bai C.X. et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir. Med. 2014; 2 (3): 187–194. DOI: 10.1016/S2213-2600(13)70286-8.Zheng J.P., Kang J., Huang S.Q. et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet. 2008; 371 (9629): 2013–2018. DOI: 10.1016/S0140-6736(08)60869-7.Zheng J.P., Kang J., Huang S.Q. et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet. 2008; 371 (9629): 2013–2018. DOI: 10.1016/S0140-6736(08)60869-7.Cazzola M., Rogliani P., Calzetta L. et al. Impact of mucolytic agents on COPD exacerbations: a pair-wise and network meta-analysis. COPD. 2017; 14 (5): 552‒563. DOI: 10.1080/15412555.2017.1347918.Cazzola M., Rogliani P., Calzetta L. et al. Impact of mucolytic agents on COPD exacerbations: a pair-wise and network meta-analysis. COPD. 2017; 14 (5): 552‒563. DOI: 10.1080/15412555.2017.1347918.Papi A., Avdeev S., Calverley P.M.A. et al. Use of mucolytics in COPD: a Delphi consensus study. Respir. Med. 2020; 175: 106190. DOI: 10.1016/j.rmed.2020.106190.Papi A., Avdeev S., Calverley P.M.A. et al. Use of mucolytics in COPD: a Delphi consensus study. Respir. Med. 2020; 175: 106190. DOI: 10.1016/j.rmed.2020.106190.Rogers D.F. Mucoactive agents for airway mucus hypersecretory diseases. Respir. Care. 2007; 52 (9): 1176–1197. Available at: http://rc.rcjournal.com/content/52/9/1176Rogers D.F. Mucoactive agents for airway mucus hypersecretory diseases. Respir. Care. 2007; 52 (9): 1176–1197. Available at: http://rc.rcjournal.com/content/52/9/1176Zuin R., Palamidese A., Negrin R. et al. High dose N-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease. Clin. Drug Invest. 2005; 25 (6): 401–408. DOI: 10.2165/00044011-200525060-00005.Zuin R., Palamidese A., Negrin R. et al. High dose N-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease. Clin. Drug Invest. 2005; 25 (6): 401–408. DOI: 10.2165/00044011-200525060-00005.Moretti M. Pharmacology and clinical effi acy of erdosteine in chronic obstructive pulmonary disease. Expert Rev. Respir. Med. 2007; 1 (3): 307–316. DOI: 10.1586/17476348.1.3.307.Moretti M. Pharmacology and clinical effi acy of erdosteine in chronic obstructive pulmonary disease. Expert Rev. Respir. Med. 2007; 1 (3): 307–316. DOI: 10.1586/17476348.1.3.307.Hotzinger H. Erdosteine or placebo combined with co-trimoxazole in the treatment of hypersecretive infectious bronchitis: a double blind clinical trial. Med. Praxis. 1991; 12: 171–181.Hotzinger H. Erdosteine or placebo combined with co-trimoxazole in the treatment of hypersecretive infectious bronchitis: a double blind clinical trial. Med. Praxis. 1991; 12: 171–181.Zanasi A., Menarini A. Erdosteine versus N-acetylcysteine in the treatment of exacerbation of chronic bronchopneumopathies. Med. Praxis. 1991; 12: 207–217.Zanasi A., Menarini A. Erdosteine versus N-acetylcysteine in the treatment of exacerbation of chronic bronchopneumopathies. Med. Praxis. 1991; 12: 207–217.Ghiringhelli G. Cross-over study of efficacy and tolerability of erdosteine in the treatment of chronic obstructive bronchial disease in stable hypersecretive phase: controlled double-blind study vs placebo. Arch. Med. Int. 1995; 47 (4): 113–120.Ghiringhelli G. Cross-over study of efficacy and tolerability of erdosteine in the treatment of chronic obstructive bronchial disease in stable hypersecretive phase: controlled double-blind study vs placebo. Arch. Med. Int. 1995; 47 (4): 113–120.Moretti M. Erdosteine: its relevance in COPD treatment. Expert Opin. Drug Metab. Toxicol. 2009; 5 (3): 333–343. DOI: 10.1517/17425250902814790.Moretti M. Erdosteine: its relevance in COPD treatment. Expert Opin. Drug Metab. Toxicol. 2009; 5 (3): 333–343. DOI: 10.1517/17425250902814790.Dal Negro R.W., Visconti M., Micheletto C., Tognella S. Changes in blood ROS, e-NO, and some pro-inflammatory mediators in bronchial secretions following erdosteine or placebo: a controlled study in current smokers with mild COPD. Pulm. Pharmacol. Ther. 2008; 21 (2): 304–308. DOI: 10.1016/j.pupt.2007.07.004.Dal Negro R.W., Visconti M., Micheletto C., Tognella S. Changes in blood ROS, e-NO, and some pro-inflammatory mediators in bronchial secretions following erdosteine or placebo: a controlled study in current smokers with mild COPD. Pulm. Pharmacol. Ther. 2008; 21 (2): 304–308. DOI: 10.1016/j.pupt.2007.07.004.Braga P. Bacterial adhesion to human cells. In: Edi-Aipo Scientifica. Pisa; 2000: 1–63.Braga P. Bacterial adhesion to human cells. In: Edi-Aipo Scientifica. Pisa; 2000: 1–63.Ricevuti G., Nazzone A., Uccelli E. et al. Influence of erdosteine, a mucolytic agent, on amoxicillin penetration into sputum in patients with an infective exacerbation of chronic bronchitis. Thorax. 1988; 43 (8): 585–590. DOI: 10.1136/thx.43.8.585.Ricevuti G., Nazzone A., Uccelli E. et al. Influence of erdosteine, a mucolytic agent, on amoxicillin penetration into sputum in patients with an infective exacerbation of chronic bronchitis. Thorax. 1988; 43 (8): 585–590. DOI: 10.1136/thx.43.8.585.Moretti M., Bottrighi P., Dallari R. et al. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE study. Drugs Exp. Clin. Res. 2004; 30 (4): 143–152.Moretti M., Bottrighi P., Dallari R. et al. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE study. Drugs Exp. Clin. Res. 2004; 30 (4): 143–152.Cazzola M., Floriani I., Page C.P. The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data. Pulm. Pharmacol. Ther. 2010; 23 (2): 135–144. DOI: 10.1016/j.pupt.2009.10.002.Cazzola M., Floriani I., Page C.P. The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data. Pulm. Pharmacol. Ther. 2010; 23 (2): 135–144. DOI: 10.1016/j.pupt.2009.10.002.Decramer M., Rutten-van Mölken M., Dekhuijzen P.N.R. et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet. 2005; 365 (9470): 1552–1560. DOI: 10.1016/S0140-6736(05)66456-2.Decramer M., Rutten-van Mölken M., Dekhuijzen P.N.R. et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet. 2005; 365 (9470): 1552–1560. DOI: 10.1016/S0140-6736(05)66456-2.Jenkins C.R., Postma D.S., Anzueto A.R. et al. Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease. BMC Pulm. Med. 2015; 15: 97. DOI: 10.1186/s12890-015-0077-0.Jenkins C.R., Postma D.S., Anzueto A.R. et al. Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease. BMC Pulm. Med. 2015; 15: 97. DOI: 10.1186/s12890-015-0077-0.Braga P.C., Dal Sasso M., Sala M., Gianelle V. Effects of erdosteine and its metabolites on bacterial adhesiveness. Arzneimittelforschung. 1999; 49 (4): 344–350. DOI: 10.1055/s-0031-1300425.Braga P.C., Dal Sasso M., Sala M., Gianelle V. Effects of erdosteine and its metabolites on bacterial adhesiveness. Arzneimittelforschung. 1999; 49 (4): 344–350. DOI: 10.1055/s-0031-1300425.Dal Negro R.W., Wedzicha J.A., Iversen M. et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. Eur. Respir. J. 2017; 50 (4): 1700711. DOI: 10.1183/13993003.00711-2017.Dal Negro R.W., Wedzicha J.A., Iversen M. et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. Eur. Respir. J. 2017; 50 (4): 1700711. DOI: 10.1183/13993003.00711-2017.Calverley P.M., Page C., Dal Negro R.W. et al. Effect of erdosteine on COPD exacerbations in COPD patients with moderate airflow limitation. Int. J. Chron. Obstruct. Pulmon. Dis. 2019; 14: 2733–2744. DOI: 10.2147/COPD.S221852.Calverley P.M., Page C., Dal Negro R.W. et al. Effect of erdosteine on COPD exacerbations in COPD patients with moderate airflow limitation. Int. J. Chron. Obstruct. Pulmon. Dis. 2019; 14: 2733–2744. DOI: 10.2147/COPD.S221852.Jenkins C.R., Jones P.W., Calverley P.M. et al. Effi acy of salmeterol/ fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir. Res. 2009; 10 (1): 59. DOI: 10.1186/1465-9921-10-59.Jenkins C.R., Jones P.W., Calverley P.M. et al. Effiacy of salmeterol/ fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir. Res. 2009; 10 (1): 59. DOI: 10.1186/1465-9921-10-59.Cazzola M., Page C., Roglisni P. et al. Multifaceted beneficial effects of erdosteine: more than a mucolytic agent. Drugs. 2020; 80 (17): 1799–1809. DOI: 10.1007/s40265-020-01412-x.Cazzola M., Page C., Roglisni P. et al. Multifaceted beneficial effects of erdosteine: more than a mucolytic agent. Drugs. 2020; 80 (17): 1799–1809. DOI: 10.1007/s40265-020-01412-x.Rogliani P.R., Matera M.G., Page C. et al. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine and N-acetylcysteine. Respir. Res. 2019; 20 (1): 104. DOI: 10.1186/s12931-019-1078-y.Rogliani P.R., Matera M.G., Page C. et al. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine and N-acetylcysteine. Respir. Res. 2019; 20 (1): 104. DOI: 10.1186/s12931-019-1078-y.Wedzicha J.A., Banerji D., Chapman K.R. et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N. Engl. J. Med. 2016; 374 (23): 2222–2234. DOI: 10.1056/nejmoa1516385.Wedzicha J.A., Banerji D., Chapman K.R. et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N. Engl. J. Med. 2016; 374 (23): 2222–2234. DOI: 10.1056/nejmoa1516385.Martinez F.J., Vestbo J., Anderson J. et al. Eff of fl icasone furoate and vilanterol on exacerbations of COPD in patients with moderate airflow obstruction. Am. J. Respir. Crit. Care Med. 2017; 195 (7): 881–888. DOI: 10.1164/rccm.201607-1421OC.Martinez F.J., Vestbo J., Anderson J. et al. Eff of flicasone furoate and vilanterol on exacerbations of COPD in patients with moderate airflow obstruction. Am. J. Respir. Crit. Care Med. 2017; 195 (7): 881–888. DOI: 10.1164/rccm.201607-1421OC.

The authors declare that there are no conflicts of interest present.